Stocktoria
BridgeBio Pharma, Inc. BBIO
BridgeBio Pharma, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | — |
| R&D expense | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M |
| SG&A expense | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M | $145.7M | $94.4M | — |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M | -$474.5M | -$266.2M | -$183.7M |
| Interest expense | — | — | $81.3M | $80.4M | $46.8M | $36.7M | $8.8M | $2.5M |
| Income tax | $435,000 | $1.2M | $0 | $0 | — | — | — | — |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M | -$399.7M | -$253.6M | -$136.6M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M | -$407.2M | -$256.2M | -$138.8M |
| Cash & equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M | $356.1M | $363.8M | $436.1M |
| Inventory | $26.8M | $0 | — | — | — | — | — | — |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B | $703.6M | $631.7M | $464.9M |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B | $595.7M | $155.7M | $87.6M |
| Shareholders' equity | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870.4M | $106.3M | $473.7M | $377.2M |
| EPS (diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | — | — |
Growth · year-over-year · Revenue CAGR 52.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +126.3% | +2285.3% | -88.0% | +11.4% | +745.1% | -79.7% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.